• Macrogenics Inc., of Rockville, Md., set terms for its initial public offering of 4 million shares at $14 to $16 per share. The offering is expected to raise about $60 million to support the company’s pipeline of monoclonal antibody-based therapeutics for cancer and autoimmune disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter